Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 14

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 14
---
ability profile of AP-SA02, inform the design of a larger definitive efficacy study
to demonstrate superiority of AP-SA02 in treating complicated SAB, and form the basis for an end-of-Phase-2 meeting with the FDA which
the Company plans to hold in the second half of 2025. Subject to review and feedback from the FDA, we are committed to developing a superiority
pivotal trial focused on phage as an alternative to broad-spectrum antibiotics and/or antibiotic sparing to decrease the utilization of
broad-spectrum antibiotics and their detrimental impact on the normal human microbiome.

On June 15, 2020, we entered into an agreement
(the “MTEC Agreement”) with the Medical Technology Enterprise Consortium (“MTEC”), pursuant to which we received
a $15.0 million award and entered into a multi-year program administered by the U.S. Department of Defense (the “DoD”) through
MTEC and managed by the Naval Medical Research Command – Naval Advanced Medical Development with funding from the Defense Health
Agency and Joint Warfighter Medical Research Program. On September 29, 2022, the MTEC Agreement was modified to increase the total
award by $1.3 million to $16.3 million and extend the term into the second half of 2024. On July 29, 2024, the MTEC Agreement was
modified to increase the total award by $5.3 million to $21.6 million and extend the term into the third quarter of 2025. On April 29, 2025, we received $4.65 million of additional non-dilutive award funding through MTEC, thereby increasing the total MTEC award to $26.2 million, and the MTEC Agreement was modified to extend the term to September 30, 2025. On July 2, 2025, the MTEC Agreement was modified to extend the term to March 31, 2026.We are using the award to partially fund a Phase 1b/2a,
multicenter, randomized, double-blind, placebo-controlled dose escalation study to assess the safety, tolerability and efficacy of our
phage-based candidate, AP-SA02, for the treatment of adults with S. aureus(the “diSArm” study) and to support
activities required for an end-of-Phase 2 meeting with the FDA.

Additional Clinical Indications for AP-SA02

On August